Etoricoxib
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Etoricoxib: From Pain and Inflammatory Conditions to Migraine Disorder
One-Sentence Summary
Etoricoxib is a selective COX-2 inhibitor marketed in Singapore as a painkiller and anti-inflammatory drug. The TxGNN model predicts it may be effective for migraine disorder, but there are 0 clinical trials and only 1 publication (a scoping review that does not test etoricoxib in migraine), so the prediction currently rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence records. Published pharmacology sources list rheumatoid arthritis, osteoarthritis, chronic lower back pain, ankylosing spondylitis, acute pain and gout. |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the data compiled for this report. Based on known pharmacology, etoricoxib is a selective COX-2 inhibitor (target: PTGS2). It reduces the synthesis of prostaglandin E2 (PGE2), a mediator of pain and inflammation.
PGE2 and neurogenic inflammation are thought to contribute to migraine, so the link is biologically plausible. NSAIDs are already widely used for migraine. However, the only publication retrieved for migraine disorder is a scoping review of fasting-induced headache during Ramadan, which does not test etoricoxib. The high score is therefore a computational prediction, not a clinical finding.
Other predictions in the same list are closer to existing evidence. For the broader headache disorder category, several case reports and small series describe etoricoxib helping primary stabbing headache, indomethacin-responsive headaches and secondary cough headache. For trigeminal autonomic cephalalgia, one observational report suggests that some indomethacin-responsive headaches respond to etoricoxib. These are low-level, uncontrolled observations.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 42841395 | 2026 | Review | Pain management | Scoping review of headache attributed to fasting during Ramadan. It does not test etoricoxib in migraine. |
For context, publications retrieved for related headache predictions (not for migraine disorder itself):
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35277974 | 2022 | Case series | Headache | Etoricoxib- and celecoxib-sensitive indomethacin-responsive headache disorders. |
| 29209105 | 2017 | Preclinical | Mediators of Inflammation | NSAIDs including etoricoxib affected CGRP and PGE2 release in rat trigeminal ganglia. |
| 36893522 | 2023 | Case report | Clin Neurol Neurosurg | Two patients with secondary cough headache responded to etoricoxib. |
| 17883876 | 2007 | Case report | J Med Case Reports | Etoricoxib used for idiopathic stabbing headache. |
| 18171381 | 2008 | Case report/series | Eur J Neurol | Primary stabbing headache can respond to etoricoxib. |
| 25229174 | 2014 | Case report (adverse event) | Clin Neuropharmacol | Reversible cerebral vasoconstriction syndrome possibly induced by etoricoxib. |
Singapore Market Information
Twenty valid single-ingredient licences are registered, all oral film-coated tablets. The licence records do not include approved indication text. Five examples:
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN14943P | EXINEF TABLET 60 MG | Film-coated tablet | Not stated in the record |
| SIN14944P | EXINEF TABLET 90 MG | Film-coated tablet | Not stated in the record |
| SIN16426P | Arcoxib F.C. Tablet 60 mg | Film-coated tablet | Not stated in the record |
| SIN16515P | ETOHOPE FILM-COATED TABLET 120 mg | Film-coated tablet | Not stated in the record |
| SIN16234P | ETOSHINE FILM COATED TABLETS 90MG | Film-coated tablet | Not stated in the record |
Safety Considerations
- Drug Interactions: The only interaction record is the pharmacological target (COX-2), with no graded interaction level. A published case describes life-threatening hyperkalaemia and acute kidney dysfunction when etoricoxib was taken with telmisartan and a potassium-rich low-sodium diet.
- Cardiovascular and renal risk: COX-2 inhibitors carry cardiovascular and renal risks, including fluid retention and hypertension. A case report links etoricoxib to reversible cerebral vasoconstriction syndrome, which is relevant in patients with headache.
Please refer to the package insert for full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The migraine prediction is supported only by a model score and a mechanistic argument. No trials exist, and the one retrieved publication does not evaluate etoricoxib for migraine. Related headache disorders (headache disorder, trigeminal autonomic cephalalgia) have somewhat more support, but only from case-level observations, so the evidence level is at most L4 there.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA, which is a blocking gap for safety screening
- Detailed mechanism-of-action data
- Controlled clinical evidence of etoricoxib in migraine, or a systematic review of COX-2 inhibitors in migraine
- A cardiovascular, renal and cerebrovascular risk assessment for headache patients
- Consideration of a narrower, better-supported target such as indomethacin-responsive headache disorders
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.